S evere acute respiratory coro- navirus 2 (SARS-CoV2) and the resulting acute respiratory distress syndrome (coronavirus disease 2019 [COVID-19]) is respon- sible for a worldwide pandemic, with more than 10 million cases re- ported as of June 28, 2020. S1 Although severe disease requiring hospitalization is characterized by pneumonia and respiratory failure, a significant proportion also develop acute kidney injury. Within critical care admissions with COVID-19, 16% to 35% are reported as requiring renal replacement therapy (RRT). 1–3,S2,S3 There is increasing recognition of an associated coagulopathy in hos- pitalized patients characterized by a prothrombotic state and increased venous thromboembo- lism. This brief review presents the current understanding of the coagulopathy associated with COVID-19, the risk of venous thrombosis, and the impact of this on management of RRT in crit- ically ill patients with COVID-19.
展开▼
